Insight into Novel Treatment for Cognitive Dysfunctions across Disorders

Thomas D Prevot; Guanguan Li; James M Cook; Etienne Sibille

doi:10.1021/acschemneuro.9b00148

Insight into Novel Treatment for Cognitive Dysfunctions across Disorders

ACS Chem Neurosci. 2019 May 15;10(5):2088-2090. doi: 10.1021/acschemneuro.9b00148. Epub 2019 Mar 28.

Authors

Thomas D Prevot^{1

2}, Guanguan Li³, James M Cook³, Etienne Sibille^{1

2

4}

Affiliations

¹ Campbell Family Mental Health Research Institute , Centre for Addiction and Mental Health , Toronto , ON M5T 1R8 , Canada.
² Department of Psychiatry , University of Toronto , Toronto , ON M5T 1R8 , Canada.
³ Department of Chemistry and Biochemistry , University of Wisconsin-Milwaukee , Milwaukee , Wisconsin 53211 , United States.
⁴ Department of Pharmacology and Toxicology , University of Toronto , Toronto , ON M5T 1R8 , Canada.

PMID: 30920790
DOI: 10.1021/acschemneuro.9b00148

Abstract

Cognitive dysfunctions, including impaired attention, learning, memory, and problem solving, occur in psychiatric diseases, such as depression, and are a hallmark of aging. Altered GABAergic signaling is similarly reported across these conditions, but therapeutic approaches are limited by pan-receptor activities of benzodiazepine-like ligands. α5-GABA-A receptor-preferring ligands uncover novel therapeutics for cognitive dysfunctions.

Keywords: Cognitive dysfunction; GABA; α5-GABAA-R.

MeSH terms

Animals
Attention / drug effects
Cognitive Dysfunction / drug therapy*
GABA-A Receptor Agonists / administration & dosage
GABA-A Receptor Agonists / therapeutic use*
Humans
Learning / drug effects
Memory / drug effects

Substances

GABA-A Receptor Agonists